DSIP (Delta Sleep-Inducing Peptide) is a nine-amino-acid neuropeptide originally isolated from rabbit brain that modulates sleep architecture — particularly deep, slow-wave sleep — and shows early evidence for stress-axis regulation and neuroprotection.
What it does
DSIP works differently from most sleep aids. Rather than hitting a single receptor and forcing sedation, it appears to tune multiple neuromodulatory systems at once — adjusting sensitivity at GABA-A receptors (the same receptor family targeted by benzodiazepines, though by a different mechanism), modulating serotonergic signaling, and interacting with delta opioid receptors. The net effect is a shift toward slow-wave sleep: Stage 3/4 deep sleep, the phase where growth hormone secretion peaks, memory consolidation happens, and cellular repair runs at full speed Koustav 2018.
Beyond sleep, DSIP appears to dampen the HPA axis — the hypothalamic-pituitary-adrenal stress-response circuit. A hyperactive HPA axis keeps cortisol elevated at night, which is one of the main reasons chronic stress destroys sleep quality. DSIP seems to normalize this, which may explain why users report effects that look more like stress-buffering than straight sedation Xiaoxiao 2024.
After more than four decades of research, the precise primary receptor remains unsettled. DSIP almost certainly acts as a neuromodulator — a peptide that adjusts the gain on existing systems rather than flipping a single switch. Its plasma half-life is extremely short (around 7 minutes), yet functional effects persist well beyond that window, which suggests downstream signaling changes rather than sustained receptor occupancy A 2021.
What the evidence shows
Sleep quality and architecture Moderate rodent evidence; limited and older human data
In a PCPA-induced insomnia mouse model (PCPA is a drug that depletes serotonin and disrupts sleep), a DSIP fusion peptide engineered to cross the blood-brain barrier significantly restored normal sleep architecture compared to controls Xiaoxiao 2024. A separate rat study found that phosphorylated DSIP — a modified form with better stability — restored both sleep architecture and spatial memory in animals exposed to high-altitude hypoxia, a condition known to severely fragment deep sleep Koustav 2018. Human trials are sparse and largely date to Soviet-era research that is difficult to independently verify. No recent rigorous RCTs in humans exist.
Neuroprotection and stroke recovery Rodent evidence only; no human trials
Two 2021 rodent studies tested DSIP and a related analog (KND peptide) in models of focal stroke and myocardial infarction. DSIP administration improved motor function recovery in rats after focal cerebral ischemia (stroke) A 2021, and the KND analog reduced brain and heart infarct size when given during reperfusion — the critical window when blood flow resumes after a blockage A 2021. The mechanism proposed involves anti-inflammatory and anti-apoptotic (cell-death-preventing) effects. This is interesting early-stage science, but remains entirely animal data.
Stress axis normalization Mechanistic plausibility; weak direct evidence
DSIP's interaction with the HPA axis — including reported reductions in cortisol and modulation of LH (luteinizing hormone, a pituitary hormone governing reproductive signaling) — points to hypothalamic involvement Koustav 2018. The stress-buffering effect is biologically coherent and may underlie its sleep benefits in stress-driven insomnia, but this has not been cleanly isolated in controlled human studies.
How it's used
In studies and self-reported protocols, doses range from 100 mcg (low, for sleep maintenance) to 200–500 mcg (moderate) to 1 mg (high) administered subcutaneously 30–60 minutes before sleep. Intranasal and intravenous routes have also been used in research settings. The peptide's half-life is roughly 7 minutes in plasma, so the window of injection-to-sleep matters less than with longer-acting compounds — the downstream neuromodulatory effect outlasts the peptide itself. Most protocols describe nightly use, though no established long-term dosing cycle exists in the published literature.
Side effects and safety
Reported side effects are mild and largely self-reported: morning grogginess, occasional mild headache, and vivid dreams. At higher doses, transient hypotension (a temporary drop in blood pressure) and oversleeping have been noted. No severe adverse events appear in the published literature. Pregnancy is considered an absolute contraindication given the HPA-axis and neuromodulatory activity and absence of safety data. Concurrent use with CNS depressants (alcohol, benzodiazepines, opioids) warrants caution given overlapping GABA and opioid receptor involvement. Long-term safety data in humans essentially does not exist — this is a significant unknown for anyone considering extended use.
Bottom line
DSIP has a plausible and interesting mechanism, reasonable rodent data for sleep architecture and neuroprotection, and almost no modern human trial evidence. It may be worth consideration for people with stress-driven, fragmented sleep who have exhausted better-studied options — but anyone expecting robust clinical validation will be disappointed. The long-term safety profile is genuinely unknown.